News in brief: Timing of anticoagulant resumption post-GI bleed; Remote monitoring of chemo side effects reduces symptom burden; Industry wants improved access to cell and gene therapies;

Timing of anticoagulant resumption not a factor in recurrent bleeding post-GI bleed Anticoagulant treatment after GI bleeding is associated with a higher risk of recurrent clinically relevant bleeding (HR 1.55) but lower risk of thromboembolism (HR 0.34) and death (HR 0.50). However the timing of resumption of anticoagulation after the index bleed does not appear ...

Already a member?

Login to keep reading.

© 2021 the limbic